Format

Send to

Choose Destination
Front Pharmacol. 2019 Feb 8;10:26. doi: 10.3389/fphar.2019.00026. eCollection 2019.

Hsp60 as a Novel Target in IBD Management: A Prospect.

Author information

1
Department of Experimental Biomedicine and Clinical Neuroscience University of Palermo (BIONEC-UniPA), Palermo, Italy.
2
Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.
3
Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, United States.
4
Department of Anatomy, Cell Biology and Physiology, American University of Beirut, Beirut, Lebanon.
5
Department of Anatomy and Cell Biology, Faculty Development Associate for Education Research, Center for Faculty Excellence, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States.
6
Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore - Institute of Marine and Environmental Technology (IMET), Baltimore, MD, United States.

Abstract

Inflammatory bowel disease (IBD) encompasses various pathological conditions similar but distinct that share a multifactorial etiology, including involvement of the intestinal barrier function, the immune system, and intestinal microorganisms. Hsp60 is a chaperonin component of the chaperoning system, present in all cells and tissues, including the intestine. It plays important roles in cell physiology outside and inside mitochondria, its canonical place of residence. However, Hsp60 can also be pathogenic in many conditions, the Hsp60 chaperonopathies, possibly including IBD. The various clinico-pathological types of IBD have a complicated mix of causative factors, among which Hsp60 can be considered a putatively important driver of events and could play an etiopathogenic role. This possibility is discussed in this review. We also indicate that Hsp60 can be a biomarker useful in disease diagnosing and monitoring and, if found active in pathogenesis, should become a target for developing new therapies. The latter are particularly needed to alleviate patient suffering and to prevent complications, including colon cancer.

KEYWORDS:

Hsp60; chaperoning system; chaperonopathy; chaperonotherapy; immune system; inflammatory bowel disease; intestinal wall; microbiota

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center